Indication
Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.
Loading your page…
Loading your page…
Irritable Bowel Syndrome
Marketing Authorisation Holder: AbbVie Deutschland GmbH & Co. KG
EMA Authorisation: 26/11/2012
INN: linaclotide
AI Drug & Interaction Analysis
Free account required
Ask Osler about Constella: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.